Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
Foghorn Therapeutics (FHTX) has appointed two new members to its Board of Directors: Neil Gallagher, M.D., Ph.D., and Stuart Duty. The clinical-stage biotechnology company, which focuses on developing medicines that correct abnormal gene expression, will benefit from their extensive biotechnology industry experience. Both new directors expressed enthusiasm about Foghorn's potential in developing selective therapies for various cancers and its capabilities in selective protein degradation.
Foghorn Therapeutics (FHTX) ha nominato due nuovi membri nel suo Consiglio di Amministrazione: Neil Gallagher, M.D., Ph.D. e Stuart Duty. Questa società biotecnologica in fase clinica, specializzata nello sviluppo di farmaci che correggono l'espressione genica anomala, beneficerà della loro vasta esperienza nel settore biotecnologico. Entrambi i nuovi direttori hanno espresso entusiasmo riguardo al potenziale di Foghorn nello sviluppo di terapie selettive per diversi tipi di cancro e nelle sue capacità di degradazione selettiva delle proteine.
Foghorn Therapeutics (FHTX) ha incorporado a dos nuevos miembros en su Junta Directiva: Neil Gallagher, M.D., Ph.D. y Stuart Duty. Esta empresa biotecnológica en etapa clínica, que se enfoca en desarrollar medicamentos que corrigen la expresión génica anormal, se beneficiará de su amplia experiencia en la industria biotecnológica. Ambos nuevos directores expresaron entusiasmo por el potencial de Foghorn para desarrollar terapias selectivas contra varios tipos de cáncer y sus capacidades en la degradación selectiva de proteínas.
Foghorn Therapeutics (FHTX)는 이사회에 두 명의 신규 멤버인 Neil Gallagher, M.D., Ph.D.와 Stuart Duty를 임명했습니다. 비정상적인 유전자 발현을 교정하는 약물 개발에 주력하는 임상 단계의 바이오테크 회사인 이 회사는 이들의 풍부한 바이오테크 산업 경험으로부터 큰 혜택을 받을 것입니다. 두 신임 이사는 다양한 암에 대한 선택적 치료제 개발과 선택적 단백질 분해 역량에 대한 Foghorn의 잠재력에 대해 큰 기대를 표명했습니다.
Foghorn Therapeutics (FHTX) a nommé deux nouveaux membres à son conseil d'administration : Neil Gallagher, M.D., Ph.D. et Stuart Duty. Cette société biotechnologique en phase clinique, spécialisée dans le développement de médicaments corrigeant l'expression génétique anormale, bénéficiera de leur vaste expérience dans l'industrie biotechnologique. Les deux nouveaux administrateurs ont exprimé leur enthousiasme quant au potentiel de Foghorn dans le développement de thérapies sélectives contre divers cancers et ses capacités en dégradation sélective des protéines.
Foghorn Therapeutics (FHTX) hat zwei neue Mitglieder in seinen Vorstand berufen: Neil Gallagher, M.D., Ph.D. und Stuart Duty. Das biotechnologische Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten zur Korrektur abnormer Genexpression spezialisiert hat, wird von deren umfangreicher Erfahrung in der Biotech-Branche profitieren. Beide neuen Direktoren zeigten sich begeistert von Foghorns Potenzial bei der Entwicklung selektiver Therapien für verschiedene Krebsarten und den Fähigkeiten im Bereich der selektiven Proteinabbau.
- None.
- None.
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors.
“Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline.”
Dr. Gallagher added, “Foghorn is poised to successfully develop multiple highly selective therapies against challenging targets implicated in different cancers. I look forward to working with the Board of Directors and the management team to help shape the Foghorn pipeline, which has the strong potential to address unmet needs and change treatment paradigms for multiple types of cancers.”
Mr. Duty added, “I am impressed with Foghorn’s sophisticated and proven small molecule development capabilities and, particularly, their leadership in pioneering selective protein degradation. I am excited to join the Board of Directors at this important time and help maximize Foghorn’s clinical and preclinical pipeline.”
About Neil Gallagher, M.D., Ph.D.
Dr. Gallagher has over 20 years of experience at pharmaceutical and biopharmaceutical organizations leading drug development programs across several therapeutic areas, including oncology. Currently he serves as the President, Head of Research and Development at Syndax Pharmaceuticals. Prior to that he held clinical development roles at AbbVie including serving as the Chief Medical Officer, Vice President, Head of Development. Dr. Gallagher also held development positions at Amgen, spent a decade at Novartis Oncology, and earlier in his career held roles at AstraZeneca and Astex Therapeutics. He also serves on the Board of Directors of Zymeworks and as an advisor to the Board of Nouscom. Dr. Gallagher completed his fellowship in gynecological oncology at the Institute for Cancer Studies, University of Birmingham, UK, and received his medical degree from Trinity College, Dublin.
About Stuart Duty
Stuart Duty brings over 30 years of experience in finance and investment banking in biotechnology and specialty pharmaceuticals. Most recently, he served as a Senior Managing Director at Guggenheim Securities, LLC where he advised senior executives and boards on a range of financing activities and strategic transactions. Previously, he held senior roles at Piper Jaffray and Montgomery Securities and held operating roles at Oracle Partners and Curative Technologies. Mr. Duty currently serves on the Board of Directors of Achieve Life Sciences, EyePoint Pharmaceuticals and Milestone Pharmaceuticals. Mr. Duty holds a B.A. in biochemistry from Occidental College and an M.B.A. from Harvard Business School.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
Who are the new board members appointed to Foghorn Therapeutics (FHTX)?
What is Foghorn Therapeutics' (FHTX) main focus as a company?
What specific expertise will the new board members bring to Foghorn Therapeutics (FHTX)?
What therapeutic areas is Foghorn Therapeutics (FHTX) targeting?
